PMID- 31695754
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 11
DP  - 2019
TI  - Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a 
      retrospective cohort study using a Japanese hospital database.
PG  - 90
LID - 10.1186/s13098-019-0486-y [doi]
LID - 90
AB  - BACKGROUND: Guidelines for Type 2 diabetes mellitus (T2DM) management in Japan 
      provide physicians the discretion to select treatment options based on patient 
      pathophysiology of the disease. There exists a wide variation of preference for 
      initial antidiabetes drugs (AD). The current database analysis aimed to 
      understand the real world treatment patterns in drug-naive patients with T2DM in 
      Japan. METHODS: We analyzed data of patients (>/= 18 years) diagnosed with T2DM 
      between October 2012 and September 2016 from the Medical Data Vision, a Diagnosis 
      Procedure Combination database. The primary objective was to determine the 
      proportion of T2DM patients receiving each type of treatment as first-line 
      therapy among the drug-naive cohort. RESULTS: Of the 436,546 drug-naive patients, 
      224,761 received their first-line T2DM treatment in the outpatient setting. The 
      mean age of the patient population was 65.6 years at index date. Dipeptidyl 
      peptidase-4 (DPP-4) inhibitor was the most prescribed (56.8%) outpatient AD 
      monotherapy, followed by metformin (15.4%). DPP-4 inhibitors were prescribed over 
      metformin in patients with renal disease (odds ratio [OR]: 4.20; p < 0.0001), 
      coronary heart disease and stroke (OR: 2.22; p < 0.0001). Male (OR: 1.03; 
      p = 0.0026), presence of diabetic complications [retinopathy (OR: 1.33; 
      p < 0.0001), neuropathy (OR: 1.05; p = 0.0037), nephropathy (OR: 1.08; 
      p < 0.0001)] and a high baseline HbA1c (OR: 1.45; p < 0.0001) received treatment 
      intensification during 180 days. CONCLUSION: DPP-4 inhibitors were the most 
      prevalent first-line T2DM treatment followed by metformin in Japan. The findings 
      from this retrospective analysis also support the previously published web survey 
      results and can help understand the real world utilization of T2DM 
      treatment.Trial registration Retrospectively registered.
CI  - (c) The Author(s) 2019.
FAU - Morita, Yohei
AU  - Morita Y
AUID- ORCID: 0000-0002-4112-9762
AD  - 1Medical Division, Novartis Pharma K.K, Toranomon Hills, Mori Tower 23-1, 
      Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333 Japan. GRID: grid.418599.8
FAU - Murayama, Hiroki
AU  - Murayama H
AD  - 1Medical Division, Novartis Pharma K.K, Toranomon Hills, Mori Tower 23-1, 
      Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333 Japan. GRID: grid.418599.8
FAU - Odawara, Masato
AU  - Odawara M
AD  - 2Department of Diabetes, Endocrinology, Metabolism and Rheumatology, Tokyo 
      Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo, Japan. ISNI: 0000 0001 
      0663 3325. GRID: grid.410793.8
FAU - Bauer, Melissa
AU  - Bauer M
AD  - Real World Data Analytics, Novartis Global Service Center, Vista Building, Elm 
      Park Business Campus, Merrion Road, Dublin, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20191101
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC6824122
OTO - NOTNLM
OT  - Database analysis
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Drug-naive
OT  - Japan
OT  - Metformin
OT  - Real world
OT  - Treatment intensification
OT  - Type 2 diabetes mellitus
COIS- Competing interestsYohei Morita is employee of Novartis Pharma K.K. Masato 
      Odawara has served as an advisory board member for Novartis; has received 
      research grants with contracts from Novo Nordisk and Astellas; has received 
      unrestricted research grants from Daiichi Sankyo, MSD, Ono, Novartis, Astellas, 
      Sanwa Kagaku Kenkyusho, AstraZeneca, Kyowa Hakko Kirin, Kowa, Takeda, Mitsubishi 
      Tanabe, Eli Lilly, Nippon Boehringer, Sanofi, Novo Nordisk, Sumitomo Dainippon, 
      and Taisho Toyama; and has received lecture fees from Daiichi Sankyo, MSD, Ono, 
      Novartis, Astellas, Sanwa Kagaku Kenkyusho, AstraZeneca, Kyowa Hakko Kirin, Kowa, 
      Takeda, Mitsubishi Tanabe, Eli Lilly, Nippon Boehringer, Sanofi, Novo Nordisk, 
      Sumitomo Dainippon, and Taisho Toyama. Melissa Bauer and Hiroki Murayama were 
      employees of Novartis Global Service Center and Novartis Pharma K.K, respectively 
      during the conduct of this study.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/11/01
CRDT- 2019/11/08 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/10/22 00:00 [accepted]
PHST- 2019/11/08 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/11/01 00:00 [pmc-release]
AID - 486 [pii]
AID - 10.1186/s13098-019-0486-y [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2019 Nov 1;11:90. doi: 10.1186/s13098-019-0486-y. 
      eCollection 2019.